Narrative review / 2018
Elevated cholesterol is linked to breast cancer risk and poor prognosis, while cholesterol-lowering medication appears protective against recurrence.
This review examines clinical and preclinical data on the role of cholesterol and its metabolite, 27-hydroxycholesterol (27-OHC), in breast cancer pathophysiology. Cholesterol has emerged as a risk factor for breast cancer onset, and elevated cholesterol is associated with poor prognosis. While cholesterol-lowering medication is not associated with breast cancer risk, it appears protective against recurrence.
Shows an association, not proof of cause and effect.
- Study type
- Narrative review
- Who was studied
- Patients with breast cancer or at risk for breast cancer
- What was measured
- Breast cancer onset, prognosis, and recurrence
THE PAPER
The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.
Nelson ER. Mol Cell Endocrinol, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.